Cite
HARVARD Citation
Tabernero, J. et al. (2015). Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab‐Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. Oncologist. pp. 143-150. [Online].